[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"slow-transit-constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:slow-transit-constipation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100629149","preoperative-fish-oil-pn-and-prognosis-after-constipation-surgery-100629149",false,"NCT07470892","Preoperative Fish Oil PN and Prognosis After Constipation Surgery","Impact of Preoperative Fish Oil-Containing Parenteral Nutrition on Prognosis in Patients Undergoing Surgery for Constipation: A Prospective, Multicenter, Real-World Study","FOCP","Inclusion Criteria:\n\n1. Age 18 to 75 years.\n2. Meets diagnostic criteria for slow-transit constipation (STC) or megacolon and is scheduled for elective colon surgery.\n3. Nutritional Risk Screening 2002 (NRS2002) score \\>=3.\n4. Receives fish oil-containing parenteral nutrition (PN) for \\>=3 days preoperatively or initiates PN for the first time postoperatively (according to the study cohort definition).\n5. Voluntarily participates in the study and provides signed informed consent.\n\nExclusion Criteria:\n\n1. Mental disorders or other conditions that prevent cooperation with treatment or follow-up.\n2. Pregnant or breastfeeding women, women planning pregnancy \u002F in a pre-pregnancy state, or women with a clear intention to become pregnant during the perioperative period or follow-up.\n3. Contraindications to surgery or parenteral nutrition.\n4. Concurrent enrollment in another study.\n5. No baseline data available before initiation of nutritional support treatment.\n6. Any other condition judged by the investigator to make the participant unsuitable for this study.","ALL","18 Years","75 Years",{"count":21,"type":22},306,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, real-world observational study to evaluate the impact of perioperative parenteral nutrition (PN) with fish oil-containing lipid emulsion on outcomes in adult patients with constipation undergoing elective colon surgery.\n\nThe study will compare two clinical nutrition strategies: (1) PN with fish oil-containing lipid emulsion started before surgery and continued after surgery, and (2) PN with fish oil-containing lipid emulsion started only after surgery. Eligible participants are adults (18-75 years) with slow-transit constipation (STC) or megacolon who are scheduled for elective colon surgery and have nutritional risk (NRS2002 score \\>=3).\n\nThe primary objective is to compare the incidence of postoperative complications between these two PN timing strategies. Secondary objectives include comparison of perioperative nutritional status, postoperative inflammatory status, prognosis, and safety outcomes.\n\nThis study will collect and analyze clinical data, laboratory indicators, perioperative recovery outcomes, follow-up assessments, and safety information in routine clinical practice. Outcomes include postoperative complication rates, changes in nutritional and inflammatory markers, bowel function recovery, length of hospital stay, constipation-related symptoms, quality of life, and adverse events. No experimental intervention will be assigned as part of this observational study.\n\nThe planned sample size is 306 participants. The findings may help optimize perioperative nutritional support strategies for patients with constipation undergoing surgery.",[26,27,28],"Constipation","Slow Transit Constipation","Megacolon","NOT_YET_RECRUITING","2026-03-10",{"date":32,"type":33},"2026-03-13","ACTUAL",{"date":35,"type":22},"2026-03",{"date":37,"type":22},"2029-09",{"name":39,"class":40},"Qianfoshan Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100614308","phase-3-efficacy-and-safety-of-lubiprostone-in-the-treatment-of-slow-transit-constipation-100614308","NCT07277907","Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation","Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation: A Multicenter, Randomized Controlled Trial","STOPS 03","Inclusion Criteria:\n\n1. Patients voluntarily participated in the study and provided signed informed consent;\n2. Met the Rome IV diagnostic criteria for functional constipation;\n3. Had fewer than 3 spontaneous bowel movements (SBMs) per week;\n4. More than 20% the radio-paque markers localized in the colon after 72 hours based on colonic transit studies;\n5. Were able to complete the bowel movement diary and study questionnaires as required by the study protocol;\n6. Agreed to use effective contraception from the time of signing the informed consent form until 3 months after the last dose of the study drug;\n7. Aged 18 years or older, both males and females.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Patients with severe outlet obstruction constipation (e.g. Oxford Grade IV or above for rectal prolapse, rectocele \\> 3.1 cm, puborectalis syndrome).\n3. Patients with hyperthyroidism or hypothyroidism.\n4. Patients with opioid-induced constipation.\n5. Patients with megacolon or megarectum.\n6. Patients with apparent mechanical intestinal obstruction.\n7. Patients with inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis).\n8. Patients with malignant tumors of the digestive system.\n9. Patients with a history of colorectal surgery.\n10. Patients with a previous history of taking lubiprostone.\n11. Patients with severe symptoms of depression or anxiety.\n12. Patients with known or suspected hypersensitivity to lubiprostone\u002Fpolyethylene glycol 4000 or any excipients.\n13. Patients requiring medications for Parkinson's disease, antipsychotics, antimanic agents, or psychostimulants.\n14. Patients with severe cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurological, or psychiatric diseases.\n15. Other patients deemed by the investigator as unsuitable for participation in this trial.",{"count":50,"type":22},346,"INTERVENTIONAL",[53],"PHASE3","Lubiprostone has established efficacy and a favorable safety profile in chronic constipation and irritable bowel syndrome with constipation (IBS-C). However, clinical data specifically supporting its use in slow-transit constipation (STC), a distinct subtype of chronic constipation, remains limited.",[27,56],"Pharmacotherapy",[27,58,59,60,61],"Lubiprostone","Polyethylene Glycol","Randomized Controlled Trial","medication","RECRUITING","2026-01-16",{"date":65,"type":33},"2026-01-20",{"date":67,"type":33},"2025-11-13",{"date":69,"type":22},"2027-11-30",{"name":71,"class":40},"Third Military Medical University",15,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":51,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100586159","msot-and-mri-for-non-invasive-assessment-of-intestinal-transit-time-in-children-with-chronic-bowel-emptying-disorders-100586159","NCT06911749","MSOT and MRI for Non-invasive Assessment of Intestinal Transit Time in Children With Chronic Bowel Emptying Disorders","Contrast Enhanced Multispectral Optoacoustic Tomography and MRI for Non-invasive Assessment of Intestinal Transit Time in Children With Chronic Bowel Emptying Disorders","Inclusion Criteria:\n\nPatient Group\n\n* Written informed consent from the participant (starting at age 6).\n* Written informed consent from the legal guardian(s).\n* Suspected or confirmed diagnosis of chronic defecation disorder.\n* Age ≤ 18 years.\n* Willingness and ability to participate, with sufficient German language skills to understand the informed consent document.\n\nControl Group\n\n* Written informed consent from the participant.\n* Age \\> 18 years.\n* BMI \\\u003C 25 or medical suitability for MSOT examination as assessed by a physician.\n* Willingness and ability to participate, with sufficient German language skills to understand the informed consent document.\n\nExclusion Criteria:\n\n* Age \\\u003C 1 year.\n* Pregnancy or breastfeeding.\n* Tattoos in the examination area.\n* Subcutaneous fat tissue thickness \\> 3 cm.\n* Known hypersensitivity to ICG, sodium iodide, or iodine.\n* Thyroid dysfunction, including hyperthyroidism or focal\u002Fdiffuse thyroid autonomy.\n* Recent thyroid function testing with radioactive iodine treatment (within two weeks before or after the study).\n* Impaired renal function.\n* Use of specific medications, including:\n\n  * Beta-blockers,\n  * Anticonvulsants,\n  * Cyclopropane,\n  * Bisulfite compounds,\n  * Haloperidol,\n  * Heroin,\n  * Meperidine,\n  * Metamizole,\n  * Methadone,\n  * Morphine,\n  * Nitrofurantoin,\n  * Opium alkaloids,\n  * Phenobarbital,\n  * Phenylbutazone,\n  * Probenecid,\n  * Rifamycin,\n  * Any injection containing sodium bisulfite.\n* General contraindications for MRI, such as electrical implants (e.g., pacemakers, perfusion pumps).\n* Severe claustrophobia preventing MRI examination.",true,"1 Year",{"count":83,"type":22},20,[85],"NA","The project presented here is a monocentric clinical study conducted by the Pediatric Surgery and Pediatrics departments of the University Hospital Erlangen. The study aims to experimentally expand the diagnostic approach for patients aged 0-17 years suffering from chronic bowel emptying disorders, regardless of any underlying causal or previously treated conditions.\n\nAt the core of this clinical study is the application of Multispectral Optoacoustic Tomography (MSOT) in combination with the oral contrast agent Indocyanine Green (ICG) to measure gastrointestinal transit time in children. Unlike conventional X-ray diagnostics, MSOT is radiation-free and considered non-invasive, although it has not yet been standardized for routine clinical use. Additionally, a contrast-free, non-invasive MRI technique will be employed to assess the peristalsis of intestinal segments.\n\nThe study aims to standardize the collection and evaluation of patient data following the administration of ICG and subsequent measurements using MSOT and MRI. The objective is to assess gastrointestinal transit time and peristalsis and, ultimately, to optimize therapy for affected patients. This is of particular importance in the coloproctology specialist consultation within the Pediatric Surgery and Pediatrics departments, as follows:\n\nIt enables differentiation between patients with slow transit constipation and outlet obstruction.\n\nIt allows for a more targeted application and evaluation of neuromodulation therapy, which is used within clinical studies.\n\nThis approach allows for the identification of specific intestinal segments with delayed transit time, enabling targeted electrical stimulation of these regions.\n\nA control group of healthy adult volunteers will participate in the study on a voluntary basis.",[88,27,89,90],"Chronic Constipation","Intestinal Transit Disorder","Hirschsprungs Disease",[92,93,94,95,90],"slow transit constipation","MSOT","ICG","gastrointestinal transit","2025-08-31",{"date":98,"type":33},"2025-09-03",{"date":100,"type":33},"2025-04-15",{"date":102,"type":22},"2026-06-01",{"name":104,"class":40},"Dr. med. Sonja Diez",1]